Despite the great efficacy of endocrine agents in treating ER+ breast cancer patients, relapse and outgrowth of cancer cells occurs in many patients with primary disease and invariably in metastatic disease.42 Therefore, identification of new treatment options is of paramount importance. The gene discussed is ESR1; the disease is breast carcinoma.